glp-1 agonist fda approval Novo Nordisk's Wegovy® pill (oral semaglutide 25 mg, once daily) has just been approved by the US as the first oral GLP‑1 receptor for long‑term weight management and CV risk GLP-1 Weight Loss NYC |

Description

Other eating disorders frequently associated with overweight and obesity are atypical anorexia nervosa, bulimia nervosa, and bulimia nervosa of low frequency and/or limited duration

If confirmed, these drugs could offer a novel pharmacological approach to addressing both metabolic and behavioral disorders, bridging the gap between metabolic health and neuropsychiatric conditions

Yes, but with a caveat

[DOI] [PMC free article] [PubMed] [Google Scholar] 69.Cardiovascular effects of glucagon-like peptide-1 receptor agonists

[DOI] [PMC free article] [PubMed] [Google Scholar] 49.Yamane S, Harada N, Inagaki N (2016) Mechanisms of fat-induced gastric inhibitory polypeptide/glucose-dependent insulinotropic polypeptide secretion from K cells